

# Hepeng Jia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1764012/publications.pdf>

Version: 2024-02-01

65  
papers

714  
citations

758635

12  
h-index

580395

25  
g-index

67  
all docs

67  
docs citations

67  
times ranked

735  
citing authors

#	ARTICLE	IF	CITATIONS
1	China approves first gene therapy. <i>Nature Biotechnology</i> , 2004, 22, 3-4.	9.4	224
2	China offers alternative gateway for experimental drugs. <i>Nature Biotechnology</i> , 2006, 24, 117-118.	9.4	57
3	Unbalanced progress: The hard road from science popularisation to public engagement with science in China. <i>Public Understanding of Science</i> , 2014, 23, 32-37.	1.6	45
4	Is It All a Conspiracy? Conspiracy Theories and People's Attitude to COVID-19 Vaccination. <i>Vaccines</i> , 2021, 9, 1051.	2.1	40
5	Encountered but Not Engaged: Examining the Use of Social Media for Science Communication by Chinese Scientists. <i>Science Communication</i> , 2017, 39, 646-672.	1.8	26
6	Who will win the future of display technologies?. <i>National Science Review</i> , 2018, 5, 427-431.	4.6	26
7	China ramps up efforts to commercialize GM rice. <i>Nature Biotechnology</i> , 2004, 22, 642-642.	9.4	25
8	Chinese green light for GM rice and maize prompts outcry. <i>Nature Biotechnology</i> , 2010, 28, 390-391.	9.4	22
9	I Wear a Mask for My Country: Conspiracy Theories, Nationalism, and Intention to Adopt Covid-19 Prevention Behaviors at the Later Stage of Pandemic Control in China. <i>Health Communication</i> , 2023, 38, 543-551.	1.8	21
10	Controversial Chinese gene-therapy drug entering unfamiliar territory. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 269-270.	21.5	17
11	GM phobia spreads in South Asia. <i>Nature Biotechnology</i> , 2012, 30, 1017-1018.	9.4	17
12	Passport to a Mighty Nation: Exploring Sociocultural Foundation of Chinese Public's Attitude to COVID-19 Vaccine Certificates. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10439.	1.2	16
13	China beckons to clinical trial sponsors. <i>Nature Biotechnology</i> , 2005, 23, 768-768.	9.4	13
14	Gene therapy finds welcoming environment in China. <i>Nature Medicine</i> , 2006, 12, 263-264.	15.2	13
15	When scientific literacy meets nationalism: Exploring the underlying factors in the Chinese public's belief in COVID-19 conspiracy theories. <i>Chinese Journal of Communication</i> , 2022, 15, 227-249.	1.3	13
16	Scientific collaborations shine on Belt and Road. <i>National Science Review</i> , 2017, 4, 652-657.	4.6	12
17	Agriculture: science and technology safeguard sustainability. <i>National Science Review</i> , 2019, 6, 595-600.	4.6	12
18	Chinese biotech hamstrung by production issues. <i>Nature Biotechnology</i> , 2007, 25, 147-148.	9.4	11

#	ARTICLE	IF	CITATIONS
19	Frequent cases force China to face up to scientific fraud. <i>Nature Medicine</i> , 2006, 12, 867-867.	15.2	10
20	China pushes liver proteomics. <i>Nature Biotechnology</i> , 2004, 22, 136-136.	9.4	9
21	China syndrome—a regulatory framework in meltdown?. <i>Nature Biotechnology</i> , 2007, 25, 835-837.	9.4	8
22	GM labeling in China beset by problems. <i>Nature Biotechnology</i> , 2003, 21, 835-836.	9.4	7
23	Chinese manufacturers vie for piece of outsourcing pie. <i>Nature Biotechnology</i> , 2007, 25, 1337-1338.	9.4	7
24	IP litigation in China could drive innovation. <i>Nature Biotechnology</i> , 2004, 22, 368-368.	9.4	5
25	Chinese vaccine developers gain WHO imprimatur. <i>Nature Biotechnology</i> , 2011, 29, 471-472.	9.4	5
26	China moves to reform biotech policies. <i>Nature Biotechnology</i> , 2004, 22, 1197-1197.	9.4	4
27	RESEARCH FACILITIES: China Supersizes Its Science. <i>Science</i> , 2007, 315, 1354-1356.	6.0	4
28	Regulators scramble to tighten loopholes after heparin debacle. <i>Nature Biotechnology</i> , 2008, 26, 477-478.	9.4	4
29	Road to international publications: an empirical study of Chinese communication scholars. <i>Asian Journal of Communication</i> , 2017, 27, 172-192.	0.6	4
30	Biotech parks proliferate, despite concerns over sustainability. <i>Nature Biotechnology</i> , 2003, 21, 1259-1260.	9.4	3
31	Lack of private financing hobbles emerging biotech regions. <i>Nature Biotechnology</i> , 2006, 24, 7-9.	9.4	3
32	China tightens IP protection, but concerns linger. <i>Nature Biotechnology</i> , 2009, 27, 787-788.	9.4	3
33	Newsmaker: Biocentury Transgene. <i>Nature Biotechnology</i> , 2011, 29, 12-12.	9.4	3
34	Keeping a lid on open science. <i>Nature</i> , 2017, 545, S62-S64.	18.7	3
35	Passive communicators: Chinese scientists'™ interaction with the media. <i>Science Bulletin</i> , 2018, 63, 402-404.	4.3	3
36	Conveyor belt structure of belt dryer: Analysis and optimization. <i>Engineering Failure Analysis</i> , 2020, 115, 104686.	1.8	3

#	ARTICLE	IF	CITATIONS
37	More engagement but less participation: China's alternative approach to public communication of science and technology. <i>Public Understanding of Science</i> , 2022, 31, 331-339.	1.6	3
38	China steps towards international M&A. <i>Nature Biotechnology</i> , 2005, 23, 159-159.	9.4	2
39	Poor enforcement could jeopardize China's drug innovation policy. <i>Nature Biotechnology</i> , 2006, 24, 1182-1183.	9.4	1
40	China kickstarts its vaccine market. <i>Nature Biotechnology</i> , 2006, 24, 375-375.	9.4	1
41	China's heparin billionaires. <i>Nature Biotechnology</i> , 2010, 28, 637-637.	9.4	1
42	China's new WHO flu monitoring center seeks to reverse criticism. <i>Nature Medicine</i> , 2011, 17, 520-520.	15.2	1
43	China overhauls drug regulation agency. <i>Nature Biotechnology</i> , 2013, 31, 375-375.	9.4	1
44	China's watchdog clamps down on genome sequencing services. <i>Nature Biotechnology</i> , 2014, 32, 511-511.	9.4	1
45	Strong spending compounds chemistry prowess. <i>Nature</i> , 2018, 564, S68-S69.	13.7	1
46	Yielding results to feed a people. <i>Nature</i> , 2018, 564, S62-S63.	13.7	1
47	How to find a job in China. <i>Nature</i> , 2018, 553, S4-S7.	13.7	1
48	Paleontology: advancing China's international leadership. <i>National Science Review</i> , 2019, 6, 171-176.	4.6	1
49	Visibility challenges for Asian scientists. <i>Nature Reviews Physics</i> , 2020, 2, 178-180.	11.9	1
50	Chinese biotechs wrestle with transparency, cultural hurdles. <i>Nature Biotechnology</i> , 2011, 29, 377-378.	9.4	0
51	China clampdown on GSK linked to drug costs. <i>Nature Biotechnology</i> , 2013, 31, 861-861.	9.4	0
52	Alliances for scientific success. <i>Nature</i> , 2015, 528, S187-S189.	13.7	0
53	A league of their own. <i>Nature</i> , 2017, 550, S186-S187.	13.7	0
54	Neighbours in knowledge. <i>Nature</i> , 2017, 550, S188-S191.	13.7	0

#	ARTICLE	IF	CITATIONS
55	We have confidence to lead gravitational-wave science: an interview with Yueliang Wu. National Science Review, 2017, 4, 718-720.	4.6	0
56	Using science to conquer haze: an interview with Tong Zhu. National Science Review, 2017, 4, 867-869.	4.6	0
57	China reshuffles science governance. C&EN Global Enterprise, 2018, 96, 17-17.	0.0	0
58	Discovery central. Nature, 2018, 563, S16-S17.	13.7	0
59	Core values. Nature, 2018, 558, S14-S15.	13.7	0
60	China strengthens its campaign against scientific misconduct. C&EN Global Enterprise, 2019, 97, 29-29.	0.0	0
61	China targets single-use plastics. C&EN Global Enterprise, 2020, 98, 13-13.	0.0	0
62	Diagnosing COVID-19. C&EN Global Enterprise, 2020, 98, 5-5.	0.0	0
63	Chinese agchem giant set to emerge. C&EN Global Enterprise, 2020, 98, 11-11.	0.0	0
64	Air pollution levels linked to stroke risk. C&EN Global Enterprise, 2020, 98, 9-9.	0.0	0
65	Chinese academics who work abroad are slower to win major honour. Nature, 2020, 577, 302-303.	13.7	0